Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0607, USA.
Osteoporos Int. 2009 Mar;20(3):463-72. doi: 10.1007/s00198-008-0674-3. Epub 2008 Jul 8.
Failure to take prescribed medication is common. The POSSIBLE US study is evaluating the impact of physician and patient characteristics on patient-reported compliance and persistence with osteoporosis medications. We report our study design and the baseline characteristics of 4,994 postmenopausal women recruited from primary care physician offices in 33 states.
The Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US) is a longitudinal cohort study of osteoporosis therapy in primary care.
Between 2004 and 2007, 134 physicians (in 33 states) enrolled postmenopausal women initiating, changing, or continuing osteoporosis medications. After completing a baseline questionnaire, participants will provide data semi-annually for up to 3 years through 2008. Physicians provide patient data at baseline and routine follow-up visits. Participants from 23 sites also signed a release regarding administrative claims data for economic analyses and validation of self-reported data.
Four thousand nine hundred and ninety-four evaluable women were recruited from internal medicine (n = 1,784), family practice (n = 1,556), obstetrics/gynecology (n = 1,556), and from one rheumatology practice (n = 98). Mean participant age was 64.3 years (SD = 9.97); 89% were Caucasian; 59% had some college education. Sixty-three percent used a single osteoporosis agent, usually a bisphosphonate. For monotherapy patients, concordance between clinic- and patient-reported medication use was lowest for patients prescribed estrogen therapy (70%) or calcium/vitamin D (72%). Obstetrician/gynecologists enrolled younger women, who were more likely to use estrogen therapy than patients enrolled by other physicians. The 934 women (19%) prescribed only calcium/vitamin D were younger than women prescribed pharmacologic therapy.
POSSIBLE US provides a unique foundation for evaluating longitudinal use of osteoporosis medications and related outcomes.
未服用规定药物的情况很常见。 POSSIBLE US 研究正在评估医生和患者特征对患者报告的骨质疏松症药物依从性和持久性的影响。我们报告了我们的研究设计和 4994 名绝经后妇女的基线特征，这些妇女是从 33 个州的初级保健医生办公室招募的。
前瞻性观察性科学研究骨质疏松症经验（POSSIBLE US）是一项针对初级保健中骨质疏松症治疗的纵向队列研究。
在 2004 年至 2007 年间，134 名医生（在 33 个州）招募了开始、改变或继续骨质疏松症药物治疗的绝经后妇女。完成基线问卷后，参与者将在 2008 年之前每半年提供最多 3 年的数据。医生在基线和常规随访就诊时提供患者数据。来自 23 个站点的参与者还签署了一份关于行政索赔数据的释放，用于经济分析和自我报告数据的验证。
从内科（n = 1784）、家庭实践（n = 1556）、妇产科（n = 1556）和一个风湿病诊所（n = 98）招募了 4994 名可评估的女性参与者。平均参与者年龄为 64.3 岁（SD = 9.97）；89%为白种人；59%具有大专以上学历。63%使用单一骨质疏松症药物，通常为双膦酸盐。对于单药治疗患者，诊所和患者报告的药物使用一致性最低的是服用雌激素治疗（70%）或钙/维生素 D（72%）的患者。妇产科医生招募的年轻女性使用雌激素治疗的可能性高于其他医生招募的患者。仅服用钙/维生素 D 的 934 名女性（19%）比服用药物治疗的女性年轻。
POSSIBLE US 为评估骨质疏松症药物的纵向使用和相关结果提供了独特的基础。
